18.737 articles found

Effect of therapy on motor cortical excitability in Parkinson's disease.

Soysal A, Sobe I, Atay T, Sen A, Arpaci B.

Can J Neurol Sci · 2008-05-01

DOI: 10.1017/s0317167100008581PMID: 18574929

Diagnostic performance of clinical motor and non-motor tests of Parkinson disease: a matched case-control study.

Bohnen NI, Studenski SA, Constantine GM, Moore RY.

Eur J Neurol · 2008-04-24

DOI: 10.1111/j.1468-1331.2008.02148.xPMID: 18435767

Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism.

Fantin M, Auberson YP, Morari M.

J Neurochem · 2008-04-24

DOI: 10.1111/j.1471-4159.2008.05439.xPMID: 18435828

Movement-related synchronization of gamma activity is lateralized in patients with dystonia.

Brücke C, Kempf F, Kupsch A, Schneider GH, Krauss JK, Aziz T, Yarrow K, Pogosyan A, Brown P, Kühn AA.

Eur J Neurosci · 2008-04-22

DOI: 10.1111/j.1460-9568.2008.06203.xPMID: 18430031

Neuroleptic-induced movement disorders in a naturalistic schizophrenia population: diagnostic value of actometric movement patterns.

Janno S, Holi MM, Tuisku K, Wahlbeck K.

BMC Neurol · 2008-04-18

DOI: 10.1186/1471-2377-8-10PMID: 18419829

Cardiac sympathetic denervation is correlated with Parkinsonian midline motor symptoms.

Kim JS, Lee KS, Song IU, Kim YI, Kim SH, You IR, Kim HT.

J Neurol Sci · 2008-04-18

DOI: 10.1016/j.jns.2008.02.017PMID: 18378259

Learning and consolidation of visuo-motor adaptation in Parkinson's disease.

Marinelli L, Crupi D, Di Rocco A, Bove M, Eidelberg D, Abbruzzese G, Ghilardi MF.

Parkinsonism Relat Disord · 2008-04-18

DOI: 10.1016/j.parkreldis.2008.02.012PMID: 18424221

USE OF 4-CYCLOPROPYLMETHOXY-N-(3,5-DICHLORO-1-OXIDOPYRIDIN-4-YL)-5-(METHOXY)PYRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF MOTOR DISORDERS RELATED TO PARKINSON'S DISEASE

DELAY-GOYET PHILIPPE, DELGORGE CLAIRE, MENET CHRISTINE, POUGHON GILLES, RAVINET-TRILLOU CHRISTINE.

· 2008-04-16

USE OF 4-CYCLOPROPYLMETHOXY-N-(3,5-DICHLORO-1-OXIDOPYRIDIN-4-YL)-5-(METHOXY)PYRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF MOTOR DISORDERS RELATED TO PARKINSON'S DISEASE

DELAY-GOYET PHILIPPE, DELGORGE CLAIRE, MENET CHRISTINE, POUGHON GILLES, RAVINET-TRILLOU CHRISTINE.

· 2008-04-16

USE OF 4-CYCLOPROPYLMETHOXY-N-(3,5-DICHLORO-1-OXIDOPYRIDIN-4-YL)-5-(METHOXY)PYRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF MOTOR DISORDERS RELATED TO PARKINSON'S DISEASE

DELAY-GOYET PHILIPPE, DELGORGE CLAIRE, MENET CHRISTINE, POUGHON GILLES, RAVINET-TRILLOU CHRISTINE.

· 2008-04-16

USE OF 4-CYCLOPROPYLMETHOXY-N-(3,5-DICHLORO-1-OXSIDOPYRIDIN-4-YL)-5-(METHOXY)PYRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF MOTOR DISORDERS RELATED TO PARKINSON'S DISEASE

DELAY-GOYET PHILIPPE, DELGORGE CLAIRE, MENET CHRISTINE, POUGHON GILLES, RAVINET-TRILLOU CHRISTINE.

· 2008-04-16

Neurotoxic lesions at the ventral mesopontine junction change sleep time and muscle activity during sleep: an animal model of motor disorders in sleep.

Lai YY, Hsieh KC, Nguyen D, Peever J, Siegel JM.

Neuroscience · 2008-04-16

DOI: 10.1016/j.neuroscience.2008.03.085PMID: 18487021